These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37324232)

  • 1. First Strike personalized predictive radioiodine prescription for inoperable metastatic differentiated thyroid cancer.
    Kao YH
    Asia Ocean J Nucl Med Biol; 2023; 11(2):158-167. PubMed ID: 37324232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer.
    Abuqbeitah M; Demir M; Kabasakal L; Çavdar İ; Uslu-Beşli L; Yeyin N; Razavikhosroshahi S; Sönmezoğlu K
    Nucl Med Commun; 2018 Nov; 39(11):969-975. PubMed ID: 30180046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.
    Sgouros G; Song H; Ladenson PW; Wahl RL
    J Nucl Med; 2006 Dec; 47(12):1977-84. PubMed ID: 17138740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics.
    Boehm E; Kao YH; Lai J; Wraight PR; Sivaratnam DA
    Clin Endocrinol (Oxf); 2022 Jul; 97(1):124-129. PubMed ID: 35508893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma.
    Van Nostrand D; Atkins F; Moreau S; Aiken M; Kulkarni K; Wu JS; Burman KD; Wartofsky L
    Thyroid; 2009 Oct; 19(10):1093-8. PubMed ID: 19732012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
    Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
    Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.
    Amdur RJ; Dan T; Mazzaferri E
    Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients.
    Jarzab B; Handkiewicz-Junak D; Roskosz J; Puch Z; Wygoda Z; Kukulska A; Jurecka-Lubieniecka B; Hasse-Lazar K; Turska M; Zajusz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1077-86. PubMed ID: 12783219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.
    Abuqbeitah M; Demir M; Çavdar İ; Tanyildizi H; Yeyin N; Uslu-Beşli L; Kabasakal L; Işıkcı Nİ; Sönmezoğlu K
    Radiat Environ Biophys; 2018 Nov; 57(4):395-404. PubMed ID: 30298289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results.
    Giostra A; Richetta E; Pasquino M; Miranti A; Cutaia C; Brusasco G; Pellerito RE; Stasi M
    Phys Med Biol; 2016 Jun; 61(11):4316-26. PubMed ID: 27200493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?
    Sun F; Gerrard GE; Roberts JK; Telford T; Namini S; Waller M; Flux G; Gill VM
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):310-315. PubMed ID: 28132755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
    Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
    Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
    Berg G; Lindstedt G; Suurküla M; Jansson S
    J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
    Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
    J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.